^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Solid Tumor
    Drug:GQ1001 (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

    Excerpt:
    ...Patients must have pathologically documented advanced/unresectable or metastatic solid tumor with HER2-positive (as defined below) that is relapsed or refractory to standard therapy or for which there is...
    Trial ID:
    NCT04450732
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Res
    Title:

    Abstract 2702: GQ1001 is a next generation HER2-targeting ADC with excellent druggability, safety and potency

    Published date:
    04/04/2023
    Excerpt:
    Consistent with this preclinical data, GQ1001 demonstrated superior tolerability profile in heavily pretreated HER2-positive advanced solid tumors patients in a global, open labeled multicenter phase Ia trial...GQ1001 demonstrates the potential to treat HER2-positive cancer patients, alone or in combination, who have progressed on previous HER2-targeting therapeutics with reduced toxicity.
    DOI:
    10.1158/1538-7445.AM2023-2702